Zusammenfassung
Primäres Ziel der Hochdruckbehandlung ist die Senkung hypertonieinduzierter kardiovaskulärer
Komplikationen und Senkung der Mortalität bei hoher Lebensqualität. Am Beginn der
therapeutischen Intervention steht die Aufklärung des Patienten über das Krankheitsbild,
seine Ursachen und Komplikationen. Die nichtmedikamentöse Therapie stellt die Basis
jeder therapeutischen Intervention dar, unabhängig vom Hypertonieschweregrad. Im Zentrum
aller Bemühungen zur Veränderung des Lebensstiles stehen dabei Maßnahmen zur Gewichtsnormalisierung.
Die Indikation beziehungsweise der Zeitpunkt des Beginns einer medikamentösen antihypertensiven
Therapie richten sich primär nach dem jeweiligen Risikostatus unter Einbeziehung der
Blutdruckwerte. Aufgrund des hohen psychologischen Stellenwertes einer möglichst geringen
Belastung des Organismus sollte die Therapie mit so wenig einzelnen „Pillen” wie möglich
konzipiert werden und frühzeitig in eine wirkungsvolle Kombinationstherapie münden.
Summary
The primary aims of the treatment of high blood pressure are the reduction of hypertension-induced
cardiovascular complications and the lowering of mortality, while preserving a high
quality of life. The therapeutic intervention begins with the education of the patient
about his/her condition, its causes and complications. Irrespective of the severity
of the hypertension, non-pharmaceutical treatment forms the basis of any therapeutic
intervention. At the centre of efforts to modify the patient's lifestyle are measures
aimed at normalising his/her weight. The indication for, and the timing of, initiation
of pharmaceutical hypertensive therapy is oriented primarily to the risk status prevailing,
with consideration being given to the blood pressure values. In view of the high psychological
value of a lowest possible burdening of the organism, treatment should be designed
to involve as few pills as possible, and should lead on to effective combination therapy
as early as possible.
Literatur
- 1
Chobanian AV, Bakris GL, Black HR. et al. .
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure.
JAMA.
2003;
289
2560-2571
- 2
De Backer G, Ambrosioni E, Borch-Johnsen K. et al. .
European Guidelines on cardiovascular disease prevention in clinical practice. Third
Joint Task Force of European and other Societies.
European Heart Journal.
2003;
24
1601-1610
- 3
Guidelines Committee .
2003 European Society of Hypertension - European Society of Cardiology guidelines
for the management of arterial hypertension.
J Hypertension.
2003;
21
1011-1053
- 4
Hansson I, Zanchetti A, Carruthers SG. et al. .
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with
hypertension: principal results of the hypertension optima treatment (HOT) randomised.
Lancet.
1998;
351
1755-1762
- 5 Julius St, Kjeldsen SE, Weber M. et al. .Outcomes in hypertensive patients at high
cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE
randomised trial. Lancet; Published online June 14: image.thelancet.com/extras/04art4187web.pdf
2004
- 6
Pepine J, Handberg EM, Cooper-DeHoff RM. et al. .
The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial.
JAMA.
2003;
21
2805-2816
- 7
Scholze J.
Pulse Pressure in der Therapiesteuerung der Hypertonie?.
Herz.
2004;
29
276-289
- 8 Scholze J. Hypertonie kompakt. Blackwell Wissenschafts-Verlag. Berlin, Wien 2002
- 9
Staessen JA, Wang JG, Thijs L.
Cardiovascular protection and blood pressure reduction: a meta-analysis.
Lancet.
2001;
358
1305-1315
- 10
The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Group .
Major outcomes in high-risk hypertensive patients randomised to angiotensin converting
enzyme inibitor or calcium channel vs diuretic. The Antihypertensive and Lipid-Lowering
treatment to prevent Heart Attack Trial (ALLHAT).
J Am Med Assoc.
2002;
160
211-220
- 11
UK Prospective Diabetes Study Group .
Tight blood pressure control and risk of macrovascular and microvascular complications
in type 2 diabetes: UKPDS 38.
BMJ.
1998;
317
703-713
- 12 Sever PS, Dahlof B, Poulter NR. et al. .A randomised controlled trial of the Prevention
of CHD by BP and Cholesterol lowering in a factorial Study design. Kongress ACC, März
2005
Anschrift des Verfassers
Prof. Dr. med. Jürgen Scholze
Medizinische Poliklinik Universitätsmedizin Berlin
Carité Campus Mitte
Luisenstraße 13
10117 Berlin
Fax: 030/450-51490
Email: juergen.scholze@charite.de
